 FLORHAM PARK, N.J., Sept. 20, 2021 GLOBE NEWSWIRE -- Phathom Pharmaceuticals, Inc. Nasdaq: PHAT, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported it has obtained a 200 million term loan facility from Hercules Capital, Inc. NYSE: HTGC, a leader in customized debt financing for companies in life sciences and technology-related markets. This additional capital further strengthens Phathoms balance sheet in advance of anticipated key catalysts, including data from the pivotal PHALCON-EE Phase 3 trial of vonoprazan for the treatment of erosive esophagitis in October 2021, data from the Phase 2 trial of vonoprazan for the treatment of non-erosive reflux disease in the first quarter of 2022, and FDA approval and commercial launch of vonoprazan-based regimens for the treatment of H. pylori in the second half of 2022. This non-dilutive financing extends Phathoms projected cash runway to mid-2023 based on the Companys current operating plans. 